Johnson & Johnson's IMBRUVICA® Receives FDA Approval for Expanded Use

Johnson & Johnson, in partnership with Pharmacyclics LLC, an AbbVie Company, revealed that the U.S. Food and Drug Administration (FDA) has granted approval for an expanded label for IMBRUVICA® (ibrutinib). This expansion introduces an oral suspension formulation tailored for adult patients undergoing treatment for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), Waldenström’s macroglobulinemia (WM), and chronic graft versus host disease (cGVHD) following the failure of one or more lines of systemic therapy.